Structure-based discovery of inhibitors of human DJ-1, a Parkinson’s disease associated protein.

Jose M.M. Caaveiro1,2,*, Shinya TASHIRO1, and Kouhei TSUMOTO1,3,*
1Dept. of Bioengineering, School of Engineering, The University of Tokyo, Tokyo 113-8656, Japan
2Global Healthcare, Graduate School of Pharmacy, Kyushu University, Fukuoka 812-8582, Japan
3Institute of Medical Science, The University of Tokyo, Tokyo 108-8639

DJ-1 is a Parkinson’s disease associated protein but its exact role in the progression of the disease remains uncertain. We have employed X-ray crystallography to identify the binding mode of low-affinity inhibitors. Based on the structural data, optimized inhibitors displaying high-affinity were obtained.

1 Introduction
Parkinson’s disease is a devastating neurodegenerative disorder [1]. The brains in patients with advanced disease are profoundly damaged, and show insufficient levels of the neurotransmitter dopamine. Mutation in the protein DJ-1 produces a condition termed early onset Parkinson’s disease [2]. Unfortunately, the molecular mechanism leading to this condition is unknown

Among the reasons hampering the characterization of DJ-1 is the absence of a well-defined inhibitor. The evidence reported so far suggested that an inhibitor binding to the Cys106 may inhibit the biological function of DJ-1. Herein, we have identified and optimized compounds with a well-defined inhibition mechanism against DJ-1. These compounds belong to the isatin family and showed strong inhibitory properties in vitro and in cell. We hope these compounds will contribute to understand the function of DJ-1 and its connection to Parkinsonism.

2 Experimental
Human DJ-1 was expressed in high-levels in Escherichia coli, and purified to homogeneity. Crystals of DJ-1 in complex with inhibitors were prepared by the soaking method. Crystals of reduced DJ-1 were obtained by the hanging-drop method by mixing the protein (20 mg mL−1) with a solution containing 100 mM Tris-HCl (pH 8.5), 200 mM sodium citrate, 30% (v/v) PEG-400, and 5 mM DTT. Crystals of DJ-1 were subsequently soaked with compounds 1 ~ 40 mM for 1 ~ 24 hr. The selected crystals were frozen in liquid N2 until data collection.

Data were collected at BL-5A, AR-NW12A and AR-NW12A of the Photon Factory (Tsukuba, Japan) under cryogenic conditions (100 K). Data were processed with MOSFLM and SCALA. Structures of DJ-1 in complex with various compounds were determined by the method of molecular replacement with PHASER and refined with REFMAC5 and COOT.

3 Results and Discussion
A screening of DJ-1 with a small library of fragment compounds found that the molecule of isatin binds to DJ-1 with significant affinity. This observation was corroborated by other techniques [3]. The crystal structure of DJ-1 in complex with isatin at 1.5 Å resolution revealed a covalent bond between the Cys106 residue and DJ-1 (Fig. 1). This is the first evidence of a small molecule directly bound to the key Cys106 of DJ-1 suggesting that isatin (and isatin-like compounds) may be a promising family of compounds inhibiting the activity of DJ-1.

The analysis of the interactions between isatin and DJ-1 revealed some critical elements necessary for binding, but also regions suitable for optimization. The structural information guided the optimization of isatin to increase the affinity. In particular the addition of a phenyl group and a halogen at specific positions increased the affinity of the compounds for the protein (Fig. 2). These compounds bind in the same conformation as isatin, and also engage in a covalent bond with Cys106.

Fig. 1: Structure of isatin (I) bound to DJ-1. (a) Position of isatin in the dimer. (b) Close-up view of the active site. (c) Environment of isatin when bound to DJ-1. Adapted from [3].

Fig. 2: Optimization of isatins. Affinity expressed as $K_d$. 

$K_d = 3.2 \mu M$ $K_d = 0.75 \mu M$ $K_d = 0.10 \mu M$
Importantly, these compounds do not only bind, but also inhibit the enzymatic activity of DJ-1 (Fig. 3). Because these compounds make a covalent bond with Cys106, it was hypothesized these compounds could behave as inhibitors. Among several biological functions, DJ-1 is an enzyme with glyoxalase and deglycation activity [4]. The enzymatic assays in the presence of several compounds indeed showed robust inhibitory properties, the fluoride/phenyl derivative having the strongest effect (compound 15) (Fig. 3).

Fig. 3: Enzymatic inhibition by isatins. Compound 2 corresponds to an isatin derivative not binding to DJ-1 because it lacks one of the carbonyl oxygens. Adapted from [3].

In summary, we have determined the crystal structure of isatin bound to human DJ-1. Based on this structure we have increased the affinity of the hit-compound and demonstrated that these compounds also inhibit the enzymatic activity of the protein. We hope these compounds will help to clarify the function of DJ-1 in Parkinsonism and other biological processes.

Acknowledgement
We thank the staff of the Photon Factory for excellent technical support. This work was supported by the Platform for Drug Discovery, Informatics and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to KT), by JSPS KAKENHI-A grants 25249115 and 16H02420 (to KT), by a JSPS KAKENHI-C grant 15K06962 (to JMMC), and by a Grant-in-Aid for JSPS Fellows (to ST).

References

*Corresponding authors: jose@phar.kyushu-u.ac.jp (JMMC), and tsumoto@bioeng.t.u-tokyo.ac.jp (KT)